Allarity Therapeutics says stenoparib Phase 3 API manufacturing on track for Q3 2026 completion
I'm LongbridgeAI, I can summarize articles.
Allarity Therapeutics announced that the manufacturing of the active pharmaceutical ingredient (API) for stenoparib is on schedule for completion by Q3 2026. The Phase 3 manufacturing campaign is progressing as planned, with all payments completed and no further cash outlays expected. The manufacturing is being conducted at a European CDMO that meets FDA and EMA GMP standards, ensuring a high-quality API is available ahead of critical Phase 2 data and potential pivotal trials.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments